PharmaShots Weekly Snapshots (April 24 - 28, 2023)
Evecxia Therapeutics Receives Notice of Allowance from the US PTO Covering EVX‑101
Date: Apr 28, 2023 | Tags: Evecxia Therapeutics, EVX‑101, Regulatory, Patent, USPTO, 17/877, 699
Zura Bio Reports $80M Financing and Licensing of ZB-106 from Eli Lilly for Autoimmune Diseases
Date: Apr 28, 2023 | Tags: Zura Bio, Eli Lilly, Tibulizumab, ZB-106, Rheumatoid Arthritis, Sjogren’s Syndrome Pharma, P-Ib
Date: Apr 28, 2023 | Tags: Daewoong Pharmaceutical, Vitalli Bio, DWP213388, License Agreement, Pharma, Korea, ~$477M
Date: Apr 28, 2023 | Tags: Takeda, Entyvio, Ulcerative Colitis, Regulatory, US FDA, BLA, VISIBLE 1
Date: Apr 28, 2023 | Tags: Elicio Therapeutics, ELI-002 7P, KRAS/NRAS Mutated Solid Tumors, Clinical Trial, P-I/II, AMPLIFY-7P, P-I, AMPLIFY-201
Date: Apr 28, 2023 | Tags: Innoblative, SIRA RFA, Electrosurgical Device, Breast Cancer, Medtech, Regulatory, US FDA, Breakthrough Device Designation
Date: Apr 27, 2023 | Tags: Eli Lilly, tirzepatide, Obesity, Overweight, Type 2 Diabetes, Clinical Trial, P-III, Surmount-2 Trial
Date: Apr 27, 2023 | Tags: Seres Therapeutics, Nestlé Health Science, Vowst, C. Difficile Infection, Regulatory, US, FDA, Approval
Date: Apr 27, 2023 | Tags: Ultromics, Echogo Amyloidosis, Cardiac Amyloidosis, Regulatory, Medtech, US FDA, Breakthrough Device Designation
Date: Apr 27, 2023 | Tags: Galapagos, Filgotinib, Active Axial Spondyloarthritis, Clinical Trial, P-III, Olinguito Trial
Date: Apr 27, 2023 | Tags: Novartis, Iptacopan, Paroxysmal Nocturnal Hemoglobinuria, Clinical Trial, P-III, APPOINT-PNH Trial, ebmt, 2023
Date: Apr 27, 2023 | Tags: BMS, Camzyos, Mavacamten, Symptomatic Obstructive Hypertrophic Cardiomyopathy, Regulatory, EMA, CHMP, Positive Opinion, Approval
Date: Apr 26, 2023 | Tags: Belite Bio, Tinlarebant, Stargardt Disease, Clinical Trial, P-II, LBS-008-CT02 Study, ARVO, 2023
Assertio Holdings to Acquire Spectrum Pharmaceuticals for ~$291M
Date: Apr 26, 2023 | Tags: Assertio Holdings, Spectrum Pharmaceuticals, Rolvedon, ~$291M, M&A
Morphic Reports P-IIa Trial (EMERALD-1) Results of c for the Treatment of Ulcerative Colitis
Date: Apr 26, 2023 | Tags: Morphic, MORF-057, Ulcerative Colitis, Clinical Trial, P-IIa, EMERALD-1 Trial
Date: Apr 26, 2023 | Tags: Akebia, Vafseo, Vadadustat, Symptomatic Anaemia, Chronic Kidney Disease, Regulatory, EC, Marketing Authorisation
Date: Apr 26, 2023 | Tags: Biogen, Ionis, Qalsody, Tofersen, Amyotrophic Lateral Sclerosis, Regulatory, US, FDA, Approval
Date: Apr 26, 2023 | Tags: Stablix, Vertex, Protein Stabilization Therapies, Restoracs, Biotech
Date: Apr 25, 2023 | Tags: Samsung Bioepis, SB15, Biosimilar, Eylea, Aflibercept, Neovascular Age-Related Macular Degeneration, P-III study, ARVO, 2023
Date: Apr 25, 2023 | Tags: GSK, Jemperli, Dostarlimab, dMMR/MSI-H, Endometrial Cancer, Regulatory, EMA, MAA
Date: Apr 25, 2023 | Tags: Newamsterdam Pharma, Obicetrapib, Heterozygous Familial Hypercholesterolemia, Clinical Trial
Date: Apr 25, 2023 | Tags: Rhythm Pharmaceuticals, Imcivree, Setmelanotide, Obesity, Bardet-Biedl Syndrome, Germany, Regulatory
Eli Lilly to Sell Baqsimi to Amphastar for ~$1B
Date: Apr 25, 2023 | Tags: Eli Lilly, Amphastar, Baqsimi, Hypoglycemia, Diabetes, ~$1B, M&A
Date: Apr 25, 2023 | Tags: 3b Pharmaceuticals, Novartis, Fap-Targeting Peptide Technology, FAP-2286, P-I, Lumiere Trial, Pharma
Date: Apr 24, 2023 | Tags: Astrazeneca, Eplontersen, Hereditary Transthyretin-Mediated Amyloid Polyneuropathy, Clinical Trial, P-III, Neuro-Transform, AAN, 2023
Date: Apr 24, 2023 | Tags: Cymabay Therapeutics, Seladelpar, Primary Biliary Cholangitis, Hepatology, Clinical Trial, P-III Enhance Study
The US FDA Lifts Clinical Hold for MaaT Pharma’s MaaT013 to Treat Acute Graft-versus-Host Disease
Date: Apr 24, 2023 | Tags: Maat Pharma, MAAT013, Acute Graft-Versus-Host Disease, Clinical Trial, US, FDA, Clinical Hold
Medtronic’s MiniMed 780G System Receives the US FDA’s Approval for the Treatment of Type 1 Diabetes
Date: Apr 24, 2023 | Tags: Medtronic, Minimed 780g System, Type 1 Diabetes, Regulatory, Medtech, US, FDA, Approval
Date: Apr 24, 2023 | Tags: Lianbio, Mavacamten, Obstructive Hypertrophic Cardiomyopathy, Regulatory, NMPA, NDA, Priority Review
Date: Apr 24, 2023 | Tags: Apellis, Syfovre, Pegcetacoplan, Geographic Atrophy, Clinical Trial, P-III, Oaks, Derby
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.